✦ LIBER ✦

Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results

✍ Scribed by Sung Yoon Park; Chan Kyo Kim; Byung Kwan Park; Hyun Moo Lee; Kyung Soo Lee

Book ID: 113032783
Publisher: Springer
Year: 2010
Tongue: English
Weight: 353 KB
Volume: 21
Category: Article
ISSN: 0938-7994
DOI: 10.1007/s00330-010-1999-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Magnetic resonance imaging in the predic

Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy

✍ Michael H. Fuchsjäger; Amita Shukla-Dave; Hedvig Hricak; Liang Wang; Karim Touij 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 299 KB

ENDORECTAL MAGNETIC RESONANCE IMAGING AS

ENDORECTAL MAGNETIC RESONANCE IMAGING AS A PREDICTOR OF BIOCHEMICAL OUTCOME AFTER RADICAL PROSTATECTOMY IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER

✍ D’AMICO, ANTHONY V.; WHITTINGTON, RICHARD; MALKOWICZ, BRUCE; SCHNALL, MITCHELL; 📂 Article 📅 2000 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 71 KB

476 COMPARISON OF OBSERVED PROSTATE CANC

476 COMPARISON OF OBSERVED PROSTATE CANCER-SPECIFIC MORTALITY (PCSM) BY TREATMENT-SPECIFIC, NOMOGRAM-PREDICTED RISKS OF BIOCHEMICAL RECURRENCE (BCR) IN MEN WITH LOCALIZED PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY (RP), EXTERNAL BEAM RADIOTHERAPY (EBRT), OR BRACHYTHERAPY (PI)

✍ Lee, Byron; Stephenson, Andrew; Ciezki, Jay; Klein, Eric; Reddy, Chandana; Yu, C 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 109 KB

Can multiparametric magnetic resonance i

Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology?11Mohamed Abd-Alazeez receives funding from the Egyptian government. Mark Emberton and Hashim U. Ahmed receive funding from USHIFU and Advanced Medical Diagnostics for clinical trials. Mark Emberton is a paid consultant for Steba Biotech, USHIFU and Sanofi-Aventis. Mark Emberton has received research support by GSK for a study evaluating the role of MRI in men with prostate cancer. Mark Emberton and Hashim Ahmed have previously received medical consultancy fees from GE Healthcare/Oncura and Hashim Ahmed previously from Steba Biotech. Mark Emberton is a medical director of Mediwatch PLC. Hashim Uddin Ahmed and Mark Emberton receive funding from the Medical Research Council, the NIHR-HTA, NIHR-i4i, the US NIH/NCI, Pelican Cancer Foundation, Prostate Cancer UK, and St Peter׳s Trust. This work was part funded by research support for Mark Emberton and Alex Kirkham from the UK National Institute of Health Research UCLH/UCL Comprehensive Biomedical Research Centre, London, UK.

✍ Abd-Alazeez, Mohamed; Ahmed, Hashim U.; Arya, Manit; Allen, Clare; Dikaios, Niko 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 415 KB